1 These include imipramine (Tofranil), midodrine (ProAmatine), chlorpheniramine (Chlor-Trimeton), brompheniramine (Veltane), ephedrine (Akovaz), pseudoephedrine (Sudafed), and phenylephrine (Vazculep)
Regulatory Status Neither KLOW nor GLOW has an FDA-approved therapeutic indication
Processed data, including the complete dataset and quantitative proteomic results, are provided in the Supplementary Data Files (S1S6) as detailed in the Data Availability section
Unlike some medications that require careful tapering, GLP-1 drugs such as semaglutide, dulaglutide, and liraglutide do not typically cause physical dependence or withdrawal symptoms
Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should discuss this with their prescriber as a precaution
improved collagen organization and tensile strength (PMID: 21030672) Gastrointestinal: Protection against NSAID-induced ulcers, IBD models, fistula healing in preclinical studies (PMID: 31158953) Nerve: Enhanced sciatic nerve regeneration